Clone:
REA1233
Type of antibody:
Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC
Alternative names:
TNFRSF10B, DR5, KILLER, Ly98, MK, TRAIL-R2, TRICK2A, TRICK2B, TRICKB

Specifications for CD262 Antibody, anti-mouse, REAfinity™

Overview

Clone REA1233 recognizes the murine CD262 antigen, a protein of the TNF-receptor superfamily, expressed on leukocytes, placenta cells, liver cells and some tumor cells and tumor cell lines (such as NIH-3T3). CD262 is also known as Death receptor 5 (DR5), TRAIL-R2, and TNFRSF10B. CD262 is a receptor for TRAIL, its binding induces apoptosis by activating the NF-κB pathway.
Additional information: Clone REA1233 displays negligible binding to Fc receptors.

Alternative names

TNFRSF10B, DR5, KILLER, Ly98, MK, TRAIL-R2, TRICK2A, TRICK2B, TRICKB

Detailed product information

Technical specifications

CloneREA1233
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody, human IgG1
Hostcell line
Type of antibodyRecombinant antibodies
Speciesmouse
AntigenCD262
Alternative names of antigenTNFRSF10B, DR5, KILLER, Ly98, MK, TRAIL-R2, TRICK2A, TRICK2B, TRICKB
Molecular mass of antigen [kDa]37
Distribution of antigentumor cells, liver, placenta
Entrez Gene ID21933
RRIDAB_2819640, AB_2819641, AB_2819642, AB_2819639

Resources for CD262 Antibody, anti-mouse, REAfinity™

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for CD262 Antibody, anti-mouse, REAfinity™

Publications

  1. Hayakawa, Y. et al. (2004)
    NK cell TRAIL eliminates immature dendritic cells
    in vivo
    and limits dendritic cell vaccination efficacy.
    J. Immunol. 172(1): 123-129
  2. Sato, K et al. (2005) TRAIL-transduced dendritic cells protect mice from acute graft-versus-host disease and leukemia relapse. J. Immunol. (174): 4025-4033
  3. Takeda, K. et al. (2004) Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med. 4(199): 437-448
  4. Grisendi, G. et al. (2010) Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res. 70(9): 3718-3729
  5. Shanker, A. et al. (2008) Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J. Natl. Cancer Inst. 100(9): 649-662
  6. Iannello, A. et al. (2009) Potential role of interleukin-18 in the immunopathogenesis of AIDS: involvement in fratricidal killing of NK cells. J. Virol. 83(12): 5999-6010

Seems like you are coming from USA!
Do you want to visit our website in your country?